A small-scale 'Development Impact Bond' for hepatitis C diagnosis and treatment financing in Cameroon: the way to elimination?

# Background Many governments in low- and middle-income countries (LMICs) have difficulties paying healthcare costs upfront leading to high out-of-pocket payments for patients. A Development Impact Bond (DIB) is an innovative financing mechanism in which pr ivate investors provide pre-payment of de...

Full description

Saved in:
Bibliographic Details
Main Authors: Charlotte Michèle Dieteren, Alexander Christiaan Boers, Tatiana Mossus, Frida Essomba, Guy Wafeu, Berthe Agnouanang, William Thomas, Oudou Njoya, Roel Arnold Coutihno
Format: Article
Language:English
Published: Inishmore Laser Scientific Publishing Ltd 2023-12-01
Series:Journal of Global Health Reports
Online Access:https://doi.org/10.29392/001c.90723
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850100901996396544
author Charlotte Michèle Dieteren
Alexander Christiaan Boers
Tatiana Mossus
Frida Essomba
Guy Wafeu
Berthe Agnouanang
William Thomas
Oudou Njoya
Roel Arnold Coutihno
author_facet Charlotte Michèle Dieteren
Alexander Christiaan Boers
Tatiana Mossus
Frida Essomba
Guy Wafeu
Berthe Agnouanang
William Thomas
Oudou Njoya
Roel Arnold Coutihno
author_sort Charlotte Michèle Dieteren
collection DOAJ
description # Background Many governments in low- and middle-income countries (LMICs) have difficulties paying healthcare costs upfront leading to high out-of-pocket payments for patients. A Development Impact Bond (DIB) is an innovative financing mechanism in which pr ivate investors provide pre-payment of development program expenses. At the same time, public agencies or donors repay the investor's investment with a reasonable interest rate if the program succeeds in delivering independently measurable results that are contractually agreed upon. This study assessed quantitatively and qualitatively the feasibility of a DIB for hepatitis C Virus (HCV) diagnosis and treatment in Cameroon. # Methods A revolving fund of up to €230,000 was made available by the investor. The outcome payor reimbursed the investor only in case of good performance, defined as cured patients (HCV-RNA negative). HCV carriers who were identified were referred for treatment and tested for cure 12 weeks after completion of treatment, the outcome being validated by an independent assessor. The evaluation was guided by the six-agents model, involving interviews with relevant stakeholders (N= 22). # Results In total, 253 (98%) patients completed treatment, of which 244 (96%) are cured at week 24. We estimated that the average per-patient *outcome payment* for HCV diagnosis and treatment is €1,542, and the *average costs per treated patient* is €1,858. The investor was fully repaid, including the agreed interest and bonus. Themes or findings from the interviews confirmed the feasibility of a DIB in a low-resource setting. # Conclusions This study demonstrates that a DIB can be a suitable financing mechanism for HCV services, supporting the path towards elimination. When governments in LMICs do not have sufficient resources to fund such elimination programs upfront, such public-private partnerships can offer a solution.
format Article
id doaj-art-9ff6bd31ffeb4305a6ca02fb3b5fd09d
institution DOAJ
issn 2399-1623
language English
publishDate 2023-12-01
publisher Inishmore Laser Scientific Publishing Ltd
record_format Article
series Journal of Global Health Reports
spelling doaj-art-9ff6bd31ffeb4305a6ca02fb3b5fd09d2025-08-20T02:40:10ZengInishmore Laser Scientific Publishing LtdJournal of Global Health Reports2399-16232023-12-01710.29392/001c.90723A small-scale 'Development Impact Bond' for hepatitis C diagnosis and treatment financing in Cameroon: the way to elimination?Charlotte Michèle DieterenAlexander Christiaan BoersTatiana MossusFrida EssombaGuy WafeuBerthe AgnouanangWilliam ThomasOudou NjoyaRoel Arnold Coutihno# Background Many governments in low- and middle-income countries (LMICs) have difficulties paying healthcare costs upfront leading to high out-of-pocket payments for patients. A Development Impact Bond (DIB) is an innovative financing mechanism in which pr ivate investors provide pre-payment of development program expenses. At the same time, public agencies or donors repay the investor's investment with a reasonable interest rate if the program succeeds in delivering independently measurable results that are contractually agreed upon. This study assessed quantitatively and qualitatively the feasibility of a DIB for hepatitis C Virus (HCV) diagnosis and treatment in Cameroon. # Methods A revolving fund of up to €230,000 was made available by the investor. The outcome payor reimbursed the investor only in case of good performance, defined as cured patients (HCV-RNA negative). HCV carriers who were identified were referred for treatment and tested for cure 12 weeks after completion of treatment, the outcome being validated by an independent assessor. The evaluation was guided by the six-agents model, involving interviews with relevant stakeholders (N= 22). # Results In total, 253 (98%) patients completed treatment, of which 244 (96%) are cured at week 24. We estimated that the average per-patient *outcome payment* for HCV diagnosis and treatment is €1,542, and the *average costs per treated patient* is €1,858. The investor was fully repaid, including the agreed interest and bonus. Themes or findings from the interviews confirmed the feasibility of a DIB in a low-resource setting. # Conclusions This study demonstrates that a DIB can be a suitable financing mechanism for HCV services, supporting the path towards elimination. When governments in LMICs do not have sufficient resources to fund such elimination programs upfront, such public-private partnerships can offer a solution.https://doi.org/10.29392/001c.90723
spellingShingle Charlotte Michèle Dieteren
Alexander Christiaan Boers
Tatiana Mossus
Frida Essomba
Guy Wafeu
Berthe Agnouanang
William Thomas
Oudou Njoya
Roel Arnold Coutihno
A small-scale 'Development Impact Bond' for hepatitis C diagnosis and treatment financing in Cameroon: the way to elimination?
Journal of Global Health Reports
title A small-scale 'Development Impact Bond' for hepatitis C diagnosis and treatment financing in Cameroon: the way to elimination?
title_full A small-scale 'Development Impact Bond' for hepatitis C diagnosis and treatment financing in Cameroon: the way to elimination?
title_fullStr A small-scale 'Development Impact Bond' for hepatitis C diagnosis and treatment financing in Cameroon: the way to elimination?
title_full_unstemmed A small-scale 'Development Impact Bond' for hepatitis C diagnosis and treatment financing in Cameroon: the way to elimination?
title_short A small-scale 'Development Impact Bond' for hepatitis C diagnosis and treatment financing in Cameroon: the way to elimination?
title_sort small scale development impact bond for hepatitis c diagnosis and treatment financing in cameroon the way to elimination
url https://doi.org/10.29392/001c.90723
work_keys_str_mv AT charlottemicheledieteren asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT alexanderchristiaanboers asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT tatianamossus asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT fridaessomba asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT guywafeu asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT bertheagnouanang asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT williamthomas asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT oudounjoya asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT roelarnoldcoutihno asmallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT charlottemicheledieteren smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT alexanderchristiaanboers smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT tatianamossus smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT fridaessomba smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT guywafeu smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT bertheagnouanang smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT williamthomas smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT oudounjoya smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination
AT roelarnoldcoutihno smallscaledevelopmentimpactbondforhepatitiscdiagnosisandtreatmentfinancingincameroonthewaytoelimination